Medidata’s Next Generation Site Selection and Operational Benchmarking Tools Generally Available
NEW YORK – February 6, 2018-Targeted therapies create new opportunities for patients, but can require complex trial design to achieve their promise. These studies highlight the importance of working with the best clinical trial sites, and managing enrollment and key operational performance indicators (KPIs) in clinical development. Furthermore, regardless of study complexity, sponsors and CROs can struggle finding up-to-date, objective, quantitative sources of data on site performance and operational metrics, both within their organizations and across the industry. For over 19 years, Medidata’s unified platform has powered some of the most advanced clinical trials in the world. Today, Medidata (NASDAQ: MDSO) is taking a step further to offer the most complete data and analytics capabilities in clinical research, with new predictive analytics and benchmarking in Edge Study Feasibility and MEDS Perform. Both capabilities, now generally available, are built on MEDS - the Medidata Enterprise Data Store. MEDS is the most modern, scalable data backbone available in research, and allows sponsors and CROs to collaborate in a “give-to-get” model, powering cross-sponsor, cross-study analytics. Edge Study Feasibility accelerates patient enrollment, leveraging industry-wide de-duplicated master site data in MEDS, recommending the best sites based on their historical performance, industry experience and current study participation, inducing the use of weighted multivariate predictive models.
MEDS Perform enables research teams to measure, manage and improve operational execution across their entire portfolio of studies. Objective KPIs are automatically calculated by MEDS Perform, allowing data management and clinical operations teams to understand their own performance in the context of broader industry study execution, regardless of sponsor or CRO. ‘’Data and analytics are not only optimizing clinical research, but transforming it. The capabilities we are bringing to the market with MEDS and our investments in Data Science, inclusive of natural language processing, master data management, and predictive modeling in these cases, enable study teams to excel in creating smarter treatments,’’ said Glen de Vries, co-founder and president, Medidata. “We’re excited about the transformative impact our platform is having on clinical development, both scientifically and operationally.” About MedidataMedidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 950 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations. The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers-from study design and planning through execution, management and reporting. Medidata Contacts
Investor:
Investor:
Medidata Solutions
Betsy Frank, +1 917-522-4620
bfrank@mdsol.com
or
Anthony D’Amico, +1 732-767-4331
adamico@mdsol.com
or
Media:
Medidata Solutions
Erik Snider, +1 646-362-2997
esnider@mdsol.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
